Bahlis, N. J., Costello, C. L., Raje, N. S., Levy, M. Y., Dholaria, B., Solh, M., … Lesokhin, A. M. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. NATURE MEDICINE. https://doi.org/10.1038/s41591-023-02589

Bahlis, Nizar J., Caitlin L. Costello, Noopur S. Raje, Moshe Y. Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H. Tomasson, et al. “Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.” NATURE MEDICINE, 2023. https://doi.org/10.1038/s41591-023-02589.

Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. NATURE MEDICINE. 2023;

Bahlis, Nizar J., et al. “Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.” NATURE MEDICINE, 2023. Wos-lite, doi:10.1038/s41591-023-02589.

Bahlis NJ, Costello CL, Raje NS, Levy MY, Dholaria B, Solh M, Tomasson MH, Damore MA, Jiang S, Basu C, Skoura A, Chan EM, Trudel S, Jakubowiak A, Gasparetto C, Chu MP, Dalovisio A, Sebag M, Lesokhin AM. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. NATURE MEDICINE. 2023;